

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited
(a joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 00719)

**RESIGNATION OF EXECUTIVE DIRECTOR AND GENERAL MANAGER
AND
CEASED TO ACT AS MEMBERS OF BOARD COMMITTEES
AND
CHANGE OF ALTERNATE AUTHORISED REPRESENTATIVE**

The board of directors (the “**Board**”) of Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”) hereby announces that:

**I. RESIGNATION OF EXECUTIVE DIRECTOR AND GENERAL MANAGER, AND
CHANGE OF RELEVANT POSITIONS**

Due to work arrangements, Mr. Du Deping (杜德平) (“**Mr. Du**”) has tendered his resignation as an executive director and the general manager of the Company and has ceased to be a member of each of the Strategic Development Committee and Nomination Committee of the Board, an alternate authorised representative (as alternate to Mr. Zhang Daiming (張代銘)) of the Company (“**Alternate Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and all positions in the subsidiaries of the Company, all with effect from 1 July 2022.

Mr. Du has confirmed that, save as disclosed herein, he is not aware of any matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company and that he has no disagreement with the Board on any issues. The Board and Mr. Du also confirm that there is no matter relating to his resignation that might potentially affect the operation of the Company and its subsidiaries.

Mr. Du has demonstrated dedication and diligence in serving the Company during his tenure as an executive director and the general manager of the Company. The Board would like to express its gratitude to Mr. Du for his contributions to the Company.

Following the resignation of Mr. Du, he no longer holds any position in the Company.

The Board will appoint a new executive director and general manager as soon as possible in accordance with the Articles of Association and the relevant provisions.

II. CHANGES IN MEMBERSHIPS OF THE BOARD COMMITTEES

Upon the resignation of Mr. Du, the number and/or composition of the members of the Strategic Development Committee and the Nomination Committee of the Company will be able to meet the relevant requirements under the respective terms of reference of the committees for the time being, all such matters are not in breach of any relevant requirements under the Listing Rules. The Company is considering suitable candidates to fill the above vacancies as soon as possible.

III. CHANGE OF ALTERNATE AUTHORISED REPRESENTATIVE

Following Mr. Du's resignation as the Alternate Authorised Representative, the Company still has two authorised representatives, Mr. Zhang Daiming (張代銘) and Mr. Cao Changqiu (曹長求), and will be able to meet the requirements under Rule 3.05 of the Listing Rules. The Company is in the process of identifying a suitable candidate to fill the vacancy of Alternate Authorised Representative caused by the resignation of Mr. Du, and will publish further announcement once such appointment is confirmed.

By Order of the Board
Shandong Xinhua Pharmaceutical Company Limited
Zhang Daiming
Chairman

1 July 2022, Zibo, PRC

As at the date of this announcement, the Board comprises:

Executive Directors:
Mr. Zhang Daiming (Chairman)
Mr. He Tongqing

Independent Non-executive Directors:
Mr. Pan Guangcheng
Mr. Zhu Jianwei
Mr. Lo Wah Wai

Non-executive Directors:
Mr. Xu Lie
Mr. Cong Kechun